Clinical-epidemiological characteristic of COVID-19 and cancer, first year of pandemic

Article Sidebar

PDF
Published Nov 29, 2024
DOI: https://doi.org/10.18103/mra.v12i11.6036

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Yazmín Lizeth Martínez-Sánchez
Instituto Mexicano del Seguro Social, Hospital de Oncología Centro Médico Nacional Siglo XXI, epidemiology department, Mexico City; Mexico.
Diego Moises Tavera-Zepeda
Instituto Mexicano del Seguro Social, Hospital de Oncología Centro Médico Nacional Siglo XXI, epidemiology department, Mexico City; Mexico.
Ignacio Escobar-Munguia
nstituto Mexicano del Seguro Social, Hospital de Oncología Centro Médico Nacional Siglo XXI, internal Medicine, Mexico City; México.
Rafael Medrano-Guzmán
Instituto Mexicano del Seguro Social, Hospital de Oncología Centro Médico Nacional Siglo XXI, hospital director, Mexico City; México.

Abstract

At the end of 2021, 3.6% of the world´s population was infected by SARS-CoV2, which was one of the main causes of death in México with a fatality rate of 7.5%, being higher than the world average (1.9%). Patients with cancer were a vulnerable group to get infected and to have the worse results; in spite of the limited information to direct oncological treatment, medical care continued in Oncology hospitals. The objective of this study was to compare the clinical-epidemiological characteristics in patients with COVID-19 to those ruled out, who were hospitalized in a Third Level Cancer Hospital.


Material and methods: A cohort of oncological cases was carried out about patients who were hospitalized within 2020-2021 with a suspected diagnosis of COVID-19 and who had a RT-PCR to rule out or to confirm the diagnosis. Data related to cancer care, respiratory symptoms, laboratory report and chest x-ray were searched in the clinical record and the cases were followed for about 30 days. Simple frequencies as well as normality tests were obtained to compare the study variables between confirmed cases and those discarded through U-Mann Whitney.


Results: A total of 208 patients in which 59-year-old was the median; 49.5% were women and 50.5% were men. Colorectal cancer was the main diagnosis (19.7%). COVID-19 was confirmed in 32.2%, with dyspnea as the most common symptom (86.6%), although chills had a significant difference when comparing this group to the discarded cases, as it did elevated DHL, and an x-ray with Score≥12. During follow-up, 46.2% of patients died from this cause.


Conclusions: Chills, elevated LDH and a chest x-ray with a high Score were the main differences presented in patients with cancer and COVID-19.

Keywords: COVID-19, cancer, Mexicans, cohort.

Article Details

How to Cite
MARTÍNEZ-SÁNCHEZ, Yazmín Lizeth et al. Clinical-epidemiological characteristic of COVID-19 and cancer, first year of pandemic. Medical Research Archives, [S.l.], v. 12, n. 11, nov. 2024. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/6036>. Date accessed: 12 dec. 2024. doi: https://doi.org/10.18103/mra.v12i11.6036.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 12 No 11 (2024): November Issue, Issue 11, VOl.12
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1) Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7.

2) Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol. 2020; 92:401–402. doi:10.1002/jmv.25678.

3) Número acumulado de casos de coronavirus en el mundo desde el 22 de enero de 2020 hasta el 2 de agosto de 2023. Statista. Updated August, 2023. Accessed December 10, 2023.
https://es.statista.com/estadisticas/1104227/numeroacumulado-de-casos-de-coronavirus-covid-19-en-el-mundo-enero-marzo/.

4) Comunicado de prensa núm. 600/22. Estadísticas de defunciones registradas 2021. Instituto Nacional de Estadística y Geografía. Gobierno de México. Updated October 26, 2022. Accessed March 23, 2023. https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2022/EDR/EDR2021_10.pdf.

5) Informe Técnico Diario COVID-19 MEXICO. Gobierno de México. Updated December 31, 2021. Accessed March 23, 2023.
https://www.gob.mx/cms/uploads/attachment/file/689279/Comunicado_Tecnico_Diario_COVID-19_2021.12.27_1_.pdf.

6) Cavalcanti ID, Soares JC. Impact of COVID‐19 on cancer patients: A review. Asia Pac J Clin Oncol. 2020;17(3):186-192. doi:10.1111/ajco.13445.

7) Nahshon C, Segev Y, Schmidt M, et al. Outcomes of diagnosed COVID-19 cancer patients: Concerning results of a systematic review. J Chemother. 2021; 33(8):528-538. doi:10.1080/1120009x.2021.1899442.

8) Lee AJ, Purshouse K. COVID-19 and cancer registries: learning from the first peak of the SARS-CoV-2 pandemic. Br J Cancer. 2021;124(11)1777-1784. doi:10.1038/s41416-021-01324-x.

9) Sitanggang JS, Siregar KB, Sitanggang HH, et al. Prevalence of cancer as a comorbid in COVID-19 patients and their characteristics: A meta-analysis study. F1000Research. 2022;10:975. doi:10.12688/f1000research.53539.2.

10) Lara-Álvarez MA, Rogado-Revuelta J, Obispo-Portero B, et al. Mortalidad por COVID-19 en pacientes con cáncer en un hospital de Madrid durante las primeras 3 semanas de epidemia. Med Clin (Barc). 2020;155(5):202–204. doi:10.1016/j.medcli.2020.05.005.

11) Castelo-Branco L, Tsourti Z, Gennatas S, et al. COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMOCoCARE). ESMO Open. 2022;7(3)1-12. doi:10.1016/j.esmoop.2022.100499.

12) Ruiz-Garcia E, Peña-Nieves A, Alegria-Baños J, et al. Prognostic factors in cancer patients infected with SARS-CoV-2: a Latin American country results. Ther Adv Chronic Dis. 2021;12:1-15. doi:10.1177/20406223211047755.

13) Rees GH, Batenburg R, Scotter C. Responding to COVID-19: an exploration of EU country responses and directions for further research. BMC Health Serv Res. 2024;24(1):1198. doi:10.1186/s12913-024-11671-z.

14) Gobierno de México. Algoritmos interinos para la atención del COVID-19. Instituto Mexicano del Seguro Social. Updated July 2, 2021. Accessed October 20,2021.
http://educacionensalud.imss.gob.mx/es/coronavirus/equipos_de_respuesta.

15) Motlagh A, Yamrali M, Azghandi S, et al. COVID19 Prevention & Care; a cancer specific guideline. Arch Iran Med. 2020;23(4):255-264. doi:10.34172/aim.2020.07.

16) Sitanggang JS, Siregar KB, Sitanggang HH, Sprinse Vinolina N. Prevalence of cancer as a comorbid in COVID-19 patients and their characteristics: A meta-analysis study. F1000Research. 2022;10:975. doi:10.12688/f1000research.53539.2.

17) Luong N, Barnett I, Aledavood T. The impact of the COVID_19 pandemic on daily rhythms. J Am Med Inform Assoc. 2023;30(12):1943-1953. doi:10.1093/jamia/ocad140.

18) Taquet M, Skorniewska Z, De Deyn T, Hampshire A, Trender WR, Hellyer PJ, et al. Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK. Lancet Psychiatry. 2024;11(9):696-708. doi:10.1016/S2215-0366(24)0 0214-1.

19) Ranieri V, Gordon C, Kamboj SK, Edwars SJ. Pandemic lockdowns: who feels coerced and why? - A study on perceived coercion, perceived pressures and procedural justice during the UK COVID-19 lockdowns. BMC Public Health. 2024;24(1):793. doi:10.1186/s12889-024-17985-1.

20) Bilich T, Roerden M, Maringer Y, Nelde A, Heitmann JS, Dubbelaar ML, et al. Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer. Cancer Discov. 2021;11 (8):1982-1995. doi:10.1158/2159-8290.CD-21-0191.

21) Aboueshia M, Hussein MH, Attia AS, et al. Cancer and covid-19: Analysis of patient outcomes. Future Oncol. 2021;17(26):3499-3510. doi:10.2217/fon-2021-0121.

22) Al‐Saadi EA, Abdulnabi MA. Hematological changes associated with Covid‐19 infection. J Clin Lab Anal. 2021;36(1)1-12. doi:10.1002/jcla.24064.

23) Al-Shamsi HO, Alhazzani W, Alhuraiji A, et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: An International Collaborative Group. The Oncologist. 2020;25(6):e936-e945. doi:10.1634/theoncologist.2020-0213.

24) Ramos-Peñafiel CO, Rosas-González EA, Olarte-Carrillo I, et al. Novel coronavirus SARS-CoV-2 outbreak and cancer: A literature review. Gac Mex de Oncol. 2022;21(3):110-115. doi:10.24875/j.gamo.22000179.

25) Borghesi A, Maroldi R. Covid‑19 outbreak in Italy: Experimental chest X‑ray scoring system for quantifying and monitoring disease progression. Radiol Med 2020;125(5):509-513. doi:10.1007/s11547-020-01200-3.

26) Bairwa M, Kumar R, Beniwal K, et al. Hematological profile and biochemical markers of COVID-19 non-survivors: A retrospective analysis. Clin Epidemiol Glob Health. 2021;11:100770.
doi:10.1016/j.cegh.2021.100770

27) La Costa R. COVID-19 vaccine effectiveness in oncology patients. J Adv Pract Oncol. 2022;13 (4):441–447. doi:10.6004/jadpro.2022.13.4.6

28) Linjawi M, Hira Shakoor H, Hilary S, et al. Cancer patients during COVID-19 pandemic: A mini-review. Healthcare (Basel). 2023;11(2):248. doi:10.3390 /healthcare11020248.

29) Wang QQ. Berger NA, Xu R. Analyses of Risk, Racial Disparity, and Outcomes Among US Patients With Cancer and COVID-19 Infection. JAMA Oncol. 2021;7(2):220–227. doi:10.1001/jamaoncol.2020.6178.

30) Kelly G, Petti S, Noah N. Covid -19, non-Covid-19 and excess mortality rates not comparable across countries. Epidemiology and Infection. 149;e176:1-6. doi:10.1017/S0950268821001850.